Columbia neurologist Denise Chou, MD, explains a new breakthrough in headache medicine: the first targeted preventive therapy for migraine.
Researchers have found that treatment with very low doses of a dopamine-1 receptor (D1R) agonist was not effective in reducing the cognitive and negative symptoms of schizophrenia.
Columbia steps up efforts to explore the microbiome with a new working group and a core facility.
P&S biologists are probing the mechanisms of antibiotic resistance in bacteria to uncover new ways to restore the drugs' effectiveness.
Columbia’s Cochlear Implant Music Engineering Group is trying to reengineer and simplify music to be more enjoyable for listeners with cochlear implants.
Scientists have developed a new optical technique to study how information is transmitted in the brains of mice. Using this method, they found that only a small portion of synapses—the connections between cells that control brain activity—may be active at any given time.